[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healthy-controls-group---age-and-sex-matched\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healthy-controls-group---age-and-sex-matched":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,43,67,94,119,145,173,201],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100583769","affect-based-impulsivity-in-borderline-personality-disorder-100583769",false,"NCT06880640","Affect-based Impulsivity in Borderline Personality Disorder","Affect-based Impulsivity in Borderline Personality Disorder: Developing a Neurocomputational Phenotype","Inclusion Criteria:\n\nBorderline Personality Disorder (BPD) group:\n\n* Score of 38 or higher on Personality Assessment Inventory-Borderline Scale (PAI-BOR)\n* Participants in the BPD group will be primarily recruited from the two\n\nDEPENd lab studies that maintain large samples of BPD participants. To ensure maximal similarity between BPD participants recruited from other DEPENd lab studies and BPD participants recruited through other recruitment sources, the investigators will use the same criteria for the BPD group in the current study as the criteria used in the other DEPENd lab studies. BPD participants in the two DEPENd lab studies from which the investigators will be recruiting must meet the following criteria:\n\n1. 3+ BPD symptoms, one of which must be affective instability, per clinical interview\n2. Participants must score at least 80 on the Reynolds Intellectual Screening Test (RIST).\n\nHealth Control (HC) Group:\n\n* Score of 12 or lower on PAI-BOR\n* Score below 50th percentile on World Health Organization Disability Assessment Schedule (WHODAS)\n* Absence of any current or lifetime psychiatric disorder, including personality disorders as determined by diagnostic interviews (SIDP and SCID), if the participant had participated in the lab's other studies (IRB Nos. 20-1735 and 21-0602).\n\nCombined Inclusion Criteria:\n\n* Ages 18-45\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study\n* Willingness to participate in all components of the study\n* Participants must be able to speak, understand and read English.\n* Participants must have at least 20\u002F40 visual acuity (correct or uncorrected).\n\nExclusion Criteria:\n\n* Use of as needed antihypertensive agents within 12 hours prior to lab visit\n* Inability to refrain from using as needed psychotropic medications for 12 hours prior to lab visit\n* History of psychotic disorder, Bipolar I disorder, autism spectrum disorder, reactive attachment disorder, pervasive developmental disorder, motor disorder, head injury, mental retardation, neurological disorder, or current substance dependence\n* Family history of Bipolar I disorder in a first degree relative.\n* Participants are also excluded for any of the following: cardiac pacemaker, aneurysm clip, cochlear implants, pregnancy, shrapnel, history of metal fragments in eyes, neurostimulators, weight of 250 lbs. or more, or claustrophobia.",true,"ALL","18 Years","45 Years",{"count":21,"type":22},106,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this research study is to investigate how personality traits and neuroendocrine systems relate to decision-making patterns in individuals 18-45 years old. The main question it aims to answer is how neuroendocrine activity impacts decision-making.\n\nParticipants will complete online behavioral tasks, a stress induction procedure, self-report surveys, and a cognitive assessment. During the session, psychophysiological measures will be collected, including electrocardiogram (ECG) and cardiac impedance (ICG) to monitor heart rate and blood flow, as well as electrodermal activity (EDA), blood drop samples, and saliva collection to assess nervous system activity.",[28,29],"Borderline Personality Disorder (BPD)","Healthy Controls Group - Age and Sex-matched","RECRUITING","2026-06-25",{"date":33,"type":34},"2026-06-26","ACTUAL",{"date":36,"type":34},"2025-09-21",{"date":38,"type":22},"2026-08",{"name":40,"class":41},"University of North Carolina, Chapel Hill","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":42},"100564598","cardiopulmonary-responses-to-6-minute-stepper-test-in-bronchiectasis-versus-healthy-controls-100564598","NCT06631261","Cardiopulmonary Responses to 6-Minute Stepper Test in Bronchiectasis Versus Healthy Controls","Comparison of Cardiopulmonary Responses to 6-Minute Stepper Test Between Individuals With Bronchiectasis and Healthy Controls","Bronchiectasis group - Inclusion criteria for the study:\n\n* Being 18 years of age and older,\n* Having a clinically stable bronchiectasis,\n* To cooperate with the tests to be performed,\n* Not having a cardiovascular disease, orthopedic or neurological problem that may affect the tests,\n* Being willing to participate in the study.\n\nBronchiectasis group - Exclusion criteria:\n\n* Being in an acute exacerbation period,\n* Having a cardiovascular, orthopedic or neurological problem that may affect the tests,\n* Not being willing to participate in the study.\n\nControl group - Inclusion criteria for the study:\n\n* Being 18 years of age and older,\n* To cooperate with the tests to be performed,\n* Not having a cardiovascular, orthopedic or neurological problem that may affect the tests,\n* Being willing to participate in the study.\n\nControl group - Exclusion criteria:\n\n\\- Individuals with any known internal disease and those who do not volunteer to participate in the study will not be included in the study.",{"count":51,"type":22},60,"OBSERVATIONAL","Individuals with bronchiectasis exhibit productive cough and recurrent lung infections as well as reduced exercise capacity, physical activity level, and respiratory and peripheral muscle strength. 6-minute walk test (6MWT) is often used to assess exercise capacity in chronic lung diseases. 6MWT is recommended to be performed along a flat corridor, at least 30 m long, with low pedestrian traffic, on a hard surface. To overcome technical limitations during 6MWT, 6-minute stepper test (6MST) has been proposed to assess exercise capacity. Another test that provides information about exercise capacity is the 1-minute sit-to-stand test (1STS). To our knowledge, there is limited information about different exercise tests including 6MST and 1STS and cardiopulmonary responses to these tests in individuals with bronchiectasis. Therefore, this study aims to compare the responses to the 6MST between individuals with bronchiectasis and healthy controls and to investigate the relationships among 6MST, 6MWT, and 1STS responses and muscle strength.",[55,29],"Bronchiectasis Adult",[57,58],"Bronchiectasis","Exercise Capacity","2026-06-24",{"date":31,"type":34},{"date":62,"type":34},"2024-01-18",{"date":64,"type":22},"2027-01-18",{"name":66,"class":41},"Hacettepe University",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":16,"sex":17,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":42},"100577623","opioid-use-disorder-and-pain-100577623","NCT06800703","Opioid Use Disorder and Pain","Patients with Opioid Use Disorder (OUD)\n\nTo be eligible for inclusion in the study, an individual must meet all of the following criteria:\n\n1. Between ages 21-60 years old.\n2. Able to read and write and provide written informed consent.\n3. Meet DSM-5 criteria for moderate to severe opioid use disorder; self-reported excessive opioid use prior to study entry and verified by urine toxicology testing; seeking treatment for their OUD.\n4. Physically healthy with no major medical illnesses, history of head injury or any neurological illness\n5. No plans to relocate out of state in the next 12 months (for follow-up purposes).\n6. Currently seeking treatment or currently receiving treatment for OUD.\n7. Speak English\n8. Have been enrolled in an inpatient or outpatient treatment program for OUD for at least 4 weeks.\n\nExclusion Criteria:\n\n1. Any significant current medical condition such as neurological, cardiovascular, endocrine, renal, hepatic, thyroid pathology.\n2. History of head injury with loss of consciousness (\\> 30 minutes).\n3. Current or past DSM-IV or DSM 5 diagnosis of a major psychiatric disorder (other than opioid and nicotine use disorders) that required hospitalization, or that required daily medications for over 4 weeks. Such medications include antidepressants, anticholinergics, antipsychotics, anxiolytics, lithium, psychotropic drugs not otherwise specified including herbal products, drugs with psychomotor effects or with anxiolytics, stimulant, or antipsychotic properties, any other psychoactive drugs, and sedatives\u002Fhypnotics. Individuals with current depressive or anxiety symptoms requiring treatment or currently being treated for these symptoms will be excluded.\n4. Any subjects with foreign ferromagnetic metal objects in their body or other MR contraindications will be excluded. Individuals who previously worked in metal industry or with metal shavings (due to a risk of any remaining metal particles moving in the eye during the MRI).\n5. Pregnant or lactating women will not be recruited for the study.\n6. Cannot or are not willing to lie comfortably flat on his\u002Fher back for up to 2 hours in the MRI scanner (self-report).\n7. Body weight \\> 550 lbs. The MR scanner bed is tested to a weight limit of 550 lbs.\n8. No pPlans to relocate out of state in the next 12 months (for follow-up purposes).\n9. Still experiencing significant withdrawal symptoms.\n\nIndividuals with regular opioid use\n\nTo be eligible for inclusion in the study, an individual must meet all of the following criteria:\n\n1. Between ages 21-60 years old.\n2. Able to read and write and provide written informed consent.\n3. Use non-prescribed opioids on a weekly basis or more.\n4. Physically healthy with no major medical illnesses, history of head injury or any neurological illness\n5. No plans to relocate out of state in the next 12 months (for follow-up purposes).\n6. Speak English\n\nExclusion Criteria:\n\n1. Any significant current medical condition such as neurological, cardiovascular, endocrine, renal, hepatic, thyroid pathology.\n2. History of head injury with loss of consciousness (\\> 30 minutes).\n3. Current or past DSM-IV or DSM 5 diagnosis of a major psychiatric disorder (other than opioid and nicotine use disorders) that required hospitalization, or that required daily medications for over 4 weeks. Such medications include antidepressants, anticholinergics, antipsychotics, anxiolytics, lithium, psychotropic drugs not otherwise specified including herbal products, drugs with psychomotor effects or with anxiolytics, stimulant, or antipsychotic properties, any other psychoactive drugs, and sedatives\u002Fhypnotics. Individuals with current depressive or anxiety symptoms requiring treatment or currently being treated for these symptoms will be excluded.\n4. Any subjects with foreign ferromagnetic metal objects in their body or other MR contraindications will be excluded.\n5. Pregnant or lactating women will not be recruited for the study.\n6. Cannot or are not willing to lie comfortably flat on his\u002Fher back for up to 2 hours in the MRI scanner (self-report).\n7. Body weight \\> 550 lbs. The MR scanner bed is tested to a weight limit of 550 lbs.\n\nIndividuals with regular opioid use\n\nTo be eligible for inclusion in the study, an individual must meet all of the following criteria:\n\n1. Between ages 21-60 years old.\n2. Able to read and write and provide written informed consent.\n3. Use non-prescribed opioids on a weekly basis or more.\n4. Physically healthy with no major medical illnesses, history of head injury or any neurological illness\n5. No plans to relocate out of state in the next 12 months (for follow-up purposes).\n6. Speak English\n\nExclusion Criteria:\n\n1. Any significant current medical condition such as neurological, cardiovascular, endocrine, renal, hepatic, thyroid pathology.\n2. History of head injury with loss of consciousness (\\> 30 minutes).\n3. Current or past DSM-IV or DSM 5 diagnosis of a major psychiatric disorder (other than opioid and nicotine use disorders) that required hospitalization, or that required daily medications for over 4 weeks. Such medications include antidepressants, anticholinergics, antipsychotics, anxiolytics, lithium, psychotropic drugs not otherwise specified including herbal products, drugs with psychomotor effects or with anxiolytics, stimulant, or antipsychotic properties, any other psychoactive drugs, and sedatives\u002Fhypnotics. Individuals with current depressive or anxiety symptoms requiring treatment or currently being treated for these symptoms will be excluded.\n4. Any subjects with foreign ferromagnetic metal objects in their body or other MR contraindications will be excluded.\n5. Pregnant or lactating women will not be recruited for the study.\n6. Cannot or are not willing to lie comfortably flat on his\u002Fher back for up to 2 hours in the MRI scanner (self-report).\n7. Body weight \\> 550 lbs. The MR scanner bed is tested to a weight limit of 550 lbs.\n\nIndividuals with regular opioid use\n\nTo be eligible for inclusion in the study, an individual must meet all of the following criteria:\n\n1. Between ages 21-60 years old.\n2. Able to read and write and provide written informed consent.\n3. Use non-prescribed opioids on a weekly basis or more.\n4. Physically healthy with no major medical illnesses, history of head injury or any neurological illness\n5. No plans to relocate out of state in the next 12 months (for follow-up purposes).\n6. Speak English\n\nExclusion Criteria:\n\n1. Any significant current medical condition such as neurological, cardiovascular, endocrine, renal, hepatic, thyroid pathology.\n2. History of head injury with loss of consciousness (\\> 30 minutes).\n3. Current or past DSM-IV or DSM 5 diagnosis of a major psychiatric disorder (other than opioid and nicotine use disorders) that required hospitalization, or that required daily medications for over 4 weeks. Such medications include antidepressants, anticholinergics, antipsychotics, anxiolytics, lithium, psychotropic drugs not otherwise specified including herbal products, drugs with psychomotor effects or with anxiolytics, stimulant, or antipsychotic properties, any other psychoactive drugs, and sedatives\u002Fhypnotics. Individuals with current depressive or anxiety symptoms requiring treatment or currently being treated for these symptoms will be excluded.\n4. Any subjects with foreign ferromagnetic metal objects in their body or other MR contraindications will be excluded.\n5. Pregnant or lactating women will not be recruited for the study.\n6. Cannot or are not willing to lie comfortably flat on his\u002Fher back for up to 2 hours in the MRI scanner (self-report).\n7. Body weight \\> 550 lbs. The MR scanner bed is tested to a weight limit of 550 lbs.\n\nHealthy controls (HC) Inclusion Criteria\n\n1. Between ages 1821-60 years old.\n2. Able to read and write and provide written informed consent.\n3. Demographics matching OUD participants.\n4. Speak English\n\nExclusion Criteria:\n\n1. Meet criteria for current or history of any Axis I (except nicotine use) disorder.\n2. Any significant current medical condition such as neurological, cardiovascular, endocrine, renal, hepatic, thyroid pathology. History of head injury with loss of consciousness (\\> 30 minutes).\n\n4\\. Any subjects with foreign ferromagnetic metal objects in their body or other MR contraindications will be excluded.\n\n5\\. Pregnant or lactating women will not be recruited for the study. 6. Cannot or are not willing to lie comfortably flat on his\u002Fher back for up to 2 hours in the MRI scanner (self-report).\n\n7\\. Body weight \\> 550 lbs. The MR scanner bed is tested to a weight limit of 550 lbs.","21 Years","60 Years",{"count":76,"type":22},180,"The goal of this observational study is to characterize the brain processes of pain avoidance learning dysfunctions in individuals with opioid use disorder (OUD). The main questions it aims to answer are:\n\nCompared with healthy controls, do those with OUD exhibit impaired avoidance learning in response to pain? What are the brain processes that are associated with this avoidance learning dysfunction? Do these brain processes serve to predict future use or relapse?\n\nResearchers will compare those with OUD and healthy controls to determine avoidance learning dysfunction and its relationship with opioid use.\n\nParticipants will be performing a learning task inside an fMRI scanner. Those with OUD will also be followed up for a year to determine future opioid use.",[79,29],"Opioid Use Disorder",[81,82,83,84],"opioid use disorder","pain","avoidance learning","prediction","2026-06-12",{"date":87,"type":34},"2026-06-16",{"date":89,"type":34},"2025-02-04",{"date":91,"type":22},"2028-01",{"name":93,"class":41},"Yale University",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":23,"phases":101,"briefSummary":102,"conditions":103,"keywords":106,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":42},"100611801","neural-mechanisms-of-light-driven-analgesia-100611801","NCT07245303","Neural Mechanisms of Light Driven Analgesia","Inclusion Criteria for participants with cMSP and healthy controls (n=30)\n\n* Adults ≥18 years of age.\n* Individuals who do not have any plans for medication or treatment changes for the next 3 months.\n* Participants must be willing and able to undergo an MRI.\n* Participants must not be claustrophobic\n* Participants must be alert and oriented and able to provide informed consent.\n* Individuals must be able to speak and read English.\n\nInclusion Criteria for participants with cMSP only (n=30)\n\n* To be eligible, participants must have a score of ≥7 on the Widespread pain index (WPI) and ≥5 on the symptom severity scale (SSS), or 4-6 on the WPI and ≥9 on the SSS in the 2016 Fibromyalgia Questionnaire.\n* Pain symptoms must have been present for 3 months or longer.\n* Pain must be present in 4 out of 5 body regions.\n* Individuals enrolled will have an average pain severity ≥4 on the 0-10 NRS over the month prior to enrollment to recruit individuals with moderate to severe chronic MSP.\n\nInclusion Criteria for Participants with Congenital Stationary Night Blindness (n=2)\n\n-2 additional participants without chronic MSP will be recruited with diagnosed congenital stationary night blindness\n\nExclusion Criteria:\n\n* Presence of retinal vision disorders or conditions resulting in vision impairment.\n* Patient-reported photosensitivity, photophobia, or aversion (as may occur in autoimmune diseases such as systematic lupus erythematosus).\n* Disorders including uveitis, cataracts, color-blindness, history of seizure disorder.\n* Plans for analgesic treatment plan changes in next 3 months (surgery, analgesic medication changes, injections, pain procedures, etc).\n* Prisoner Status.\n* Pregnancy.\n* Contraindications to MRI imaging. These include the presence of implanted\u002Fembedded ferromagnetic materials, implanted medical devices that are not MRI compatible, and claustrophobia.",{"count":51,"type":22},[25],"The goal of this study will be to understand the biological mechanisms that are responsible to light-driven analgesia. Light presented to the retina has been shown to have pain relieving properties in pre-clinical and clinical studies. In this study the investigators will evaluate the functional connectivity between subcortical visual areas and non-image forming brain areas that are involved in pain sensation. The investigators will also evaluate how three colored light stimuli presented to the retina results in changes in whole brain evoked activation patterns in participants with chronic musculoskeletal pain and in healthy controls. The investigators will also assess while brain evoked activation patterns in response to a pressure pain stimulus in the presence of three light stimuli in individuals with chronic musculoskeletal pain and healthy controls.",[104,105,29],"Musculoskeletal Pain","Fibromyalgia",[107,108,109,110],"functional connectivity","colored light analgesia","functional magnetic resonance imaging","quantitative sensory testing","2026-05-08",{"date":113,"type":34},"2026-05-13",{"date":115,"type":34},"2026-02-24",{"date":117,"type":22},"2030-01-31",{"name":40,"class":41},{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":42},"100632444","emotion-regulation-in-rnt-100632444","NCT07513766","Emotion Regulation in RNT","The Neural Mechanisms of Emotion Dysregulation in Repetitive Negative Thinking (RNT) Patients: A Pilot Study","Inclusion Criteria:\n\n* Patient group: diagnosis of depression\u002FGAD\n* Healthy control group: no history of or current form of psychopathology","65 Years",{"count":128,"type":22},100,"The goal of this study is to understand why some people become stuck in repetitive negative thinking, which is common among individuals with depression and anxiety. Repetitive negative thinking involves repeatedly focusing on negative events, worries, or problems. These thoughts can be difficult to control and may worsen emotional distress and daily functioning.\n\nResearchers believe that repetitive negative thinking may be related to changes in how different brain networks communicate with each other. This study will examine how the brain responds during emotion regulation tasks in people who tend to ruminate compared with healthy individuals.\n\nTo do this, researchers will use a brain-imaging technique called functional near-infrared spectroscopy (fNIRS). This method measures brain activity using harmless infrared light while participants perform tasks on a computer.\n\nThe main questions this study aims to answer are:\n\nHow does the brain respond to emotional situations in people who experience repetitive negative thinking?\n\nAre there differences in brain activity between people with depression or anxiety and healthy individuals during emotion regulation?\n\nParticipants will include 50 healthy volunteers and 50 individuals with depression or anxiety who experience repetitive negative thinking.\n\nParticipants will:\n\nWear a lightweight brain-imaging device (fNIRS) placed on the head to measure brain activity\n\nComplete computer tasks involving emotional images and different emotion-regulation strategies, such as reinterpreting, suppressing, or distracting from emotions\n\nListen to different types of spoken feedback (criticism, praise, or neutral comments) and imagine receiving them from someone they know\n\nReport their emotional feelings during the tasks\n\nComplete several questionnaires about mood, thinking patterns, and emotional experiences\n\nDuring the experiment, researchers will also record physiological responses such as heart activity and skin reactions, which are related to emotional responses.\n\nThe results of this study may help researchers better understand the brain mechanisms underlying rumination and may contribute to the development of more effective treatments for depression and anxiety.",[131,29],"Repetitive Negative Thinking",[133,134,135],"Repetitive negative thinking","fnirs","emotion regulation","2026-03-30",{"date":138,"type":34},"2026-04-07",{"date":140,"type":34},"2024-06-05",{"date":142,"type":22},"2026-12-30",{"name":144,"class":41},"University Hospital, Ghent",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":126,"enrollmentInfo":152,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":153,"conditions":154,"keywords":156,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":172},"100631797","measurement-properties-of-the-walking-adaptability-ladder-test-and-foot-tap-test-in-multiple-sclerosis-100631797","NCT07505355","Measurement Properties of the Walking Adaptability Ladder Test and Foot Tap Test in Multiple Sclerosis","Measurement Properties of the Walking Adaptability Ladder Test and Foot Tap Test in People With Multiple Sclerosis With Mild Disability","Inclusion Criteria:\n\n* confirmed diagnosis of definite MS,\n* relapse free at least 30 days,\n* Expanded Disability Status Scale (EDSS) score between 0 and 3.5\n\nExclusion Criteria:\n\n* diagnosed with neurological disease other than MS\n* cognitive decline that renders the patient incapable of performing tests and questionnaires.\n* other neurological, orthopedic, or visual impairments affecting gait",{"count":128,"type":22},"Walking and motor control impairments are among the most common manifestations experienced by people with multiple sclerosis (pwMS) and may already be present in individuals with mild disability. Subtle changes in walking performance can reflect early disease progression, highlighting the need for sensitive clinical outcome measures that capture complex, real-world mobility. Commonly used assessments primarily quantify time or distance and may lack sensitivity to detect early or subtle functional changes in daily-life walking. Successful everyday mobility requires gait adaptability, defined as the ability to continuously adjust walking patterns in response to environmental or task-related challenges, including the processing of external perturbations and internal factors such as fatigue, balance confidence, and fear of falling. Despite its clinical relevance, gait adaptability is not specifically addressed by currently validated clinical tests in pwMS. The Walking Adaptability Ladder Test (WALT), which challenges the interaction between step length, cadence, and walking speed through continuous adjustments, and the Foot Tap Test (FTT), which assesses lower limb motor control and rhythmic coordination, have demonstrated promising measurement properties in other populations but have not yet been evaluated in pwMS. The primary aim of this study is to examine the test-retest reliability and construct validity of the WALT and FTT in pwMS with mild disability. Secondary aims include evaluating the measurement properties of the Balance Recovery Scale and the Gait-Specific Attention Scale in pwMS with mild disability, identifying inertial measurement unit-derived metrics that best discriminate pwMS with low disability from healthy controls, and exploring whether relationships between clinical motor test outcomes and self-reported measures provide complementary insights into subtle gait impairments.",[155,29],"Multiple Sclerosis",[157,158,159,160,161,162],"multiple sclerosis","walking","tapping","motor function","walking adaptability","falls","2026-03-26",{"date":165,"type":34},"2026-04-01",{"date":167,"type":34},"2025-11-10",{"date":169,"type":22},"2026-12-01",{"name":171,"class":41},"Hasselt University",4,{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":16,"sex":17,"minAge":74,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":182,"conditions":183,"keywords":186,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":200},"100576102","validating-the-on-line-creyos-cognitive-assessment-platform-in-older-adults-with-major-depressive-disorder-or-mild-cognitive-impairment-100576102","NCT06780917","Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment","Creyos-MD","General Inclusion Criteria:\n\n* Ability to read and communicate in English\n* Availability of a study partner who has regular contact with the participant\n\nGeneral Exclusion Criteria:\n\n* Lifetime DSM 5 diagnosis of schizophrenia, bipolar disorder, or OCD\n* DSM 5 diagnosis of alcohol or other substance use disorder within the past 12 months\n* High risk for suicide\n* Significant neurological conditions (e.g. stroke, seizure disorder, MS)\n* Unstable medical illnesses (e.g. uncontrolled diabetes mellitus or hypertension)\n* Taking anticonvulsants or other psychotropic medication that may interfere with cognitive testing that cannot be safely tapered and discontinued\n* Current depressive symptoms defined as a MADRS score of 10 or above\n\nSpecific Eligibility Criteria for the MCI Group:\n\nInclusion:\n\n* Aged 60 or older\n* Meets DSM 5 criteria for Minor Neurocognitive Disorder (\"MCI\")\n\nExclusion:\n\n* Having taken a cognitive enhancer within the past 6 weeks\n\nSpecific Eligibility Criteria for the rMDD Group:\n\nInclusion:\n\n* Aged 65 or older\n* Meets DSM 5 criteria for one or more major depressive episode(s) (MDE) during their adult life (i.e. 18 years of age or older) with: (a) an offset of 2 months to 5 years from the screening visit date, or (b) an offset of 5 years or more, with at least one MDE receiving medical attention (e.g. previously been on an antidepressant, saw a psychiatrist, primary care physician, or had a previous hospitalization\n\nExclusion:\n\n* Having taken a cognitive enhancer within the past 6 weeks\n* Having received electroconvulsive therapy (ECT) within 6 months of baseline neuropsychological testing\n\nSpecific Eligibility Criteria for the Control Group:\n\nInclusion:\n\n* Aged 60 or older\n\nExclusion:\n\n* Meets DSM 5 criteria for MDD at anytime during their lifetime\n* Meets DSM 5 criteria for Minor Neurocognitive Disorder (\"MCI\")",{"count":181,"type":22},150,"The goal of this observational study is to validate the Creyos online cognitive assessment platform in individuals with mild cognitive impairment, or remitted major depressive disorder. The main objectives of this research are:\n\n1. To confirm the feasibility of administering the Creyos cognitive battery to older adults with Mild Cognitive Impairment MCI) or Major Depressive Disorder in remission (rMDD).\n2. To determine whether the Creyos battery can detect changes in cognition that are predictive of changes on paper-and-pencil neuropsychological testing (\"gold standard\") over up to five years.\n\nParticipants will complete both in-person neuropsychological testing yearly as well as the Creyos online battery quarterly for up to 5 years, to allow us to compare performance on these two batteries over time.",[184,185,29],"Mild Cognitive Impairment (MCI)","Major Depressive Disorder, Remitted",[187,188,189,190],"Neuropsychological testing","Mild Cognitive Impairment","Online neuropsychological testing","Cognition","2026-03-06",{"date":193,"type":34},"2026-03-10",{"date":195,"type":34},"2025-01-13",{"date":197,"type":22},"2029-01",{"name":199,"class":41},"Centre for Addiction and Mental Health",3,{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":211,"conditions":212,"keywords":216,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":228},"100573865","innovative-multidisciplinary-strategies-for-combating-severe-dengue-100573865","NCT06751836","Innovative Multidisciplinary Strategies for Combating Severe Dengue","Advancing Pandemic Preparedness: Innovative Multidisciplinary Strategies for COMBATing Severe Dengue","COMBAT","Inclusion Criteria:\n\nGroup 1: Dengue without warning signs Patients presenting with the following symptoms confirmed positive for dengue infection by lab diagnosis by anti-dengue IgM or NS1 ELISA will be recruited for the study under this cohort.\n\nSymptoms will be fever along with at least two of the following -\n\n* Myalgia, arthralgia\n* Nausea and\u002For vomiting\n* Rashes\n* Leukopenia Group 2: DENV with warning signs This cohort will include patients with the above symptoms and any of the following clinical signs.\n* Abdominal pain with tenderness\n* Persistent vomiting\n* Fluid accumulation\n* Mucosal bleeding\n* Restlessness, lethargy\n* Liver enlargement \\>2cm\n* Laboratory findings: An increase in hematocrit levels and a rapid decrease in platelet count Group 3: Severe dengue\n* Severe plasma leakage leads to hypovolemic shock (dengue shock syndrome) and fluid accumulation with respiratory distress.\n* Severe bleeding, such as epistaxis, internal bleeding, etc., is evaluated by a clinician.\n* Severe organ involvement with any of the following symptoms\n* Liver AST or ALT ≥ 1000\n* CNS: impaired consciousness\n* Heart and other organs failure\n\nExclusion Criteria:\n\n\\-",{"count":210,"type":22},1400,"The goal of this observational study is to identify biomarkers and host factors associated with dengue severity in patients from dengue-endemic regions. The main question it aims to answer is:\n\nCan multi-omics approaches predict disease severity and identify key factors contributing to severe dengue infections?\n\nParticipants will include individuals with dengue infection, and the study will analyze their blood samples using multi-omics techniques to uncover host immune responses, disease pathogenesis, and cellular pathway interactions. The study will also assess the role of primary and secondary infections, virus serotypes, and immunological factors in disease progression. Findings aim to support disease management, improve severity prediction, and identify potential therapeutic targets to prevent severe outcomes.",[213,214,215,29],"DENV Without Warning Signs","DENV with Warning Signs","Severe Dengue",[215,217,218],"Multi-omics","Predictive biomarker","2025-02-06",{"date":221,"type":34},"2025-02-10",{"date":223,"type":34},"2025-01-03",{"date":225,"type":22},"2029-10-31",{"name":227,"class":41},"Karolinska Institutet",2]